The governing body for college sports says that the state is violating the U.S. Constitution by passing a law that confiscates the $60 million sanction imposed against Penn State in the Jerry Sandusky child-abuse case.
One day after the NCAA fired its head of enforcement for allegedly botching an investigation into the University of Miami, the Indianapolis-based organization is accusing the school of failing to control its athletic department, ESPN reported.
Roche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.
Former Amerigroup Corp. CEO James Carlson will leave WellPoint Inc., the company said Friday—three days after he was passed over for the Indianapolis-based insurer’s top job.
The Indianapolis-based National Collegiate Athletic Association asked a federal judge to throw out a Pennsylvania lawsuit challenging penalties imposed on Pennsylvania State University over the Jerry Sandusky child-abuse case.
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
The Indianapolis-based shopping mall owner reported funds from operations, a key measure of a real estate company's performance, of $2.29 a share, topping the average estimate from analysts of $2.17 a share.
Thinking that brothers Jim and John Harbaugh might go head to head in this year’s Super Bowl, Roy Fox last year filed applications to register “Harbowl” and “Harbaugh Bowl” as U.S. trademarks.
Mall owners, including Simon Property Group Inc. and General Growth Properties Inc., have been moving on from struggling retail centers as the economic rebound drives them to focus on the best-performing markets.
The Labor Department said the rapid drop in claims may be a short-term distortion. Long-term and extended claims for unemployment increased.
WellPoint Inc. is still considering former Amerigroup Corp. CEO James Carlson among several finalists to become CEO. Statements and filings this month have fueled speculation among analysts and shareholders that Carlson has vaulted ahead of other prospects.
Ardagh Group said it has agreed to buy Indiana-based glass bottle and jar manufacturer Verallia North America, which has about 4,400 employees at 13 manufacturing plants in the United States, including more than 650 workers in Indiana.
Johnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill the company is seeking to make the first in a new family of drugs for managing blood sugar.
Bank of America Corp. plans to sell 24 branches in northern Indiana and southwest Michigan with about $779 million in deposits to Old National Bancorp.
WellPoint Inc.’s plan to raise the rates for small employers in California was criticized as unreasonable by the state insurance commissioner, who said customers are being charged this year to cover U.S. health-law fees that won’t begin until 2014.
Pharmaceutical companies including Pfizer Inc., Bristol-Myers Squibb Co. and Eli Lilly and Co. could be ready to start making major acquisitions again.
Pennsylvania Gov. Tom Corbett said he will sue the Indianapolis-based National Collegiate Athletic Association, challenging a $60 million fine levied against Penn State University for its role in the Jerry Sandusky sex-abuse scandal.
Indianapolis International Airport officials are prepared to provide hundreds of stranded passengers with something to sleep on, and restaurants will stay open late to serve them.
Home repossessions rose in 29 states and the District of Columbia in November, led by an increase of 96 percent in Indiana. However, the number of homes starting on the path to foreclosure declined to the lowest level in six years.
Eli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
